StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Announces FDA Approves for its Neupogen Biosimilar NIVESTYM
July 20, 2018 4:26 PM
Pfizer Inc. (NYSE: PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Announces SWORD 100-Week Data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
July 24, 2018 5:54 AM
Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Highlights Phase III Data at AIDS 2018
July 24, 2018 5:49 AM
U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
July 20, 2018 4:24 PM